MedTrace Logo

POTS NET mRNA Functional Correlation With NET Activity

NCT03218761 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-10-14

No results posted yet for this study

Summary

DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.

Conditions

  • Postural Tachycardia Syndrome

Interventions

DIAGNOSTIC_TEST

NET mRNA level

quantification of mRNA to the Norepinephrine Transporter (NET)

DIAGNOSTIC_TEST

Plasma catechols

plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

DIAGNOSTIC_TEST

Urine Catechols

urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Dysautonomia International

    collaborator OTHER

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Satish R Raj, MD MSCI · Vanderbilt University

Eligibility

Min Age
13 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-14
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03218761 on ClinicalTrials.gov